Back to News
Market Impact: 0.25
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Agenus expects to begin enrolling patients in the next few months in a Phase 3 trial of its investigational BOT/BAL immunotherapy combination for early-stage colon cancer. Executives disclosed the timing at an investor event; no enrollment target or trial results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
AGEN0.40
More News
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook
- AI data center firm IREN delays Microsoft AI deliveries, plans $15 billion spending push
- Airbnb says it’s launching an AI travel agent in the first half of 2027